Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dementia Consortium

Eli Lilly HQ

FDA turns down Lilly and Incyte JAK inhibitor after delay

Analysts suggest safety issues in high doses

Takeda pilots Apple Watch depression app

Partners with Cognition Kit on patient monitoring wearable

- PMLiVE

NICE turns down first-line Keytruda for lung cancer

High cost of drug puts it above cost-effectiveness threshold

- PMLiVE

AZ gets US approval for diabetes combo Qtern

Wins licensing for Onglyza/Farxiga dual-therapy after rejection by the FDA in 2015

- PMLiVE

TiGenix cell therapy for Crohn’s fistulas shows long-term benefit

Phase III data for the Takeda-partnered drug raises hopes for upcoming EU approval

Lilly elects Prof Carolyn Bertozzi to board of directors

She brings oncology, inflammation and infection research expertise to the firm

- PMLiVE

FDA OKs Valeant’s psoriasis drug Siliq, with black box warning

Suicidal ideation labelling adds to challenge in rivalling Novartis’ Cosentyx and Lilly’s Taltz

- PMLiVE

Merck BACE inhibitor adds to litany of Alzheimer’s trial failures

Interim data shows “virtually no chance” of clinical success for verubecestat

Eli Lilly HQ

Lilly claims first place for JAK inhibitor Olumiant in EU

EMA approves once-daily rheumatoid arthritis drug ahead of Pfizer’s Xeljanz

- PMLiVE

Trump talks pricing and manufacturing with pharma

Heads of Celgene, Lilly, Merck & Co, Novartis and trade body PhRMA met at the White House

Celgene building

Celgene pays $300m upfront for immunology start-up Delinia

Broadens its pipeline with autoimmune disease candidate due to start trials in 2018

- PMLiVE

Takeda UK & Ireland appoints market access director

Peter Wheatley Price brings experience from GSK, Janssen and Boehringer Ingelheim

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links